David A. Siegel Sana Biotechnology, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 26,900 shares of SANA stock, worth $68,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,900

Previous 19,100 40.84%

Holding current value

$68,057

Previous $104,000 6.73%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.76 - $6.86 $29,328 - $53,508	7,800 Added 40.84%	26,900 $111,000
Q2 2024 Aug 14, 2024	BUY	$5.23 - $10.44 $99,893 - $199,404	19,100 New	19,100 $104,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $4.55 $56,840 - $92,365	-20,300 Reduced 47.54%	22,400 $91,000
Q3 2023 Nov 14, 2023	SELL	$3.77 - $6.23 $67,106 - $110,894	-17,800 Reduced 29.42%	42,700 $165,000
Q2 2023 Aug 14, 2023	BUY	$3.22 - $7.53 $322 - $753	100 Added 0.17%	60,500 $360,000
Q1 2023 May 15, 2023	BUY	$3.11 - $4.92 $55,980 - $88,560	18,000 Added 42.45%	60,400 $197,000
Q4 2022 Feb 14, 2023	SELL	$3.19 - $6.46 $56,782 - $114,988	-17,800 Reduced 29.57%	42,400 $167,000
Q3 2022 Nov 14, 2022	SELL	$5.58 - $9.04 $133,920 - $216,959	-24,000 Reduced 28.5%	60,200 $361,000
Q2 2022 Aug 15, 2022	SELL	$4.12 - $9.35 $118,244 - $268,345	-28,700 Reduced 25.42%	84,200 $541,000
Q1 2022 May 16, 2022	BUY	$5.24 - $15.58 $482,080 - $1.43 Million	92,000 Added 440.19%	112,900 $933,000
Q4 2021 Feb 14, 2022	BUY	$15.18 - $23.15 $317,262 - $483,834	20,900 New	20,900 $324,000

Others Institutions Holding SANA

# of Institutions

174

Shares Held

121M

Call Options Held

1.87M

Put Options Held

1.48M

View Full List

About Sana Biotechnology, Inc.

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $481M
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

More about SANA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account